

Ajovy's Success in Migraine Repeated in the Chinese Study

Market Event Summary

Teva's Ajovy soars in China's Phase 3 trial, promising migraine relief

Event summary and background

- Ajovy (fremanezumab) is a humanized monoclonal antibody (MAb) against the CGRP ligand that inhibits its binding to the receptor. Supported by favorable outcomes from two pivotal studies in episodic and chronic migraine, Ajovy has been approved in the major markets as a prophylactic treatment for adult migraine patients.
- In April 2024, Teva heralded a pivotal milestone as Ajovy's Phase 3 study in China (TV48125-CNS-30088) yielded positive results in the prevention of episodic or chronic migraine in adults; the drug met all designated endpoints. In contrast to placebo, it significantly reduced the frequency of migraine days per month. Teva plans to present the detailed results at a medical conference later this year.
- Migraine prophylaxis in China has historically been based on the use of generic drugs such as calcium channel blockers, antiepileptic drugs, beta blockers, and antidepressants—many prescribed off-label. However, these treatments are often ineffective, leaving an unmet need for more-efficacious therapies for migraine prophylaxis.
- Recently, major developments have occurred in the prophylactic treatment of migraine, including the approval of two anti-CGRP MAbs (Novartis's Aimovig in September 2023 and Eli Lilly's Emgality in January 2024). Additionally, under China's early access program, Ajovy has been authorized for use in the Greater Bay Area pilot zone.

Clarivate's takeaways

Commercial outlook

- Drawing from the findings of the Phase 3 TV48125-CNS-30088 study, we expect that Ajovy will secure NMPA approval as a preventive treatment for adults suffering from episodic or chronic migraine in the second half of 2025.
- As the third anti-CGRP MAb to launch in Mainland China, Ajovy's uptake is likely to be impacted by the earlier entrants—i.e., Aimovig and Emgality. We expect the product will be priced on par with the other anti-CGRP MAbs.
- Clarivate projects substantial growth of the preventive migraine therapy market—quintupling by 2032. This surge can be attributed to the launch and uptake of migraine-specific CGRP-targeted therapies, particularly anti-CGRP MAbs.

Key differentiator

Unlike other anti-CGRP MAbs, Ajovy offers both monthly and quarterly subcutaneous (SC) dosing. The convenience of the quarterly schedule, combined with Ajovy's efficacy, is expected to fuel its uptake, especially in patients who prefer less-frequent dosing. Its SC administration will give it an advantage over Vyepti (eptinezumab), another quarterly anti-CGRP MAb but one that is given intravenously. It is expected to be approved in Mainland China concurrently.

About the author



Ananya Sadhu, Ph.D.

Senior Healthcare Research and Data Analyst

Dr. Sadhu has experience in market research and competitive intelligence in various indications and has authored several syndicated reports and forecasts for various indications. Previously, she was a postdoctoral fellow at the National Centre of Biological Sciences in Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. She also worked as a scientific officer at Arvind Remedies, where she coordinated various stages of nonclinical/clinical research activities for drug development of a patented polyherbal formulation. She holds a Ph.D. in molecular biology from the National Institute of Immunology in New Delhi.

Clarivate coverage in China in 2024

- Type 2 Diabetes
- Obesity/Overweight
- Psoriasis
- Non-Small-Cell Lung Cancer
- Breast Cancer
- Ulcerative colitis
- Gastroesophageal Cancer
- Asthma
- Prostate Cancer
- Renal Cell Carcinoma
- Colorectal Cancer
- Schizophrenia
- Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
- Alzheimer's Disease
- Systemic Lupus Erythematosus



Think forward™

Have a question?

healthcare.support@clarivate.com
clarivate.com

+1 215 386 0100 (U.S.)

+44 (0) 20 7433 4000 (Europe)

About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://www.clarivate.com)

© 2024 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.